Stocks · News reference
Filed: 2026-10-29 AccNo: 0001178670-26-000074 Size: 513 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alnylam Pharmaceuticals reported positive initial Phase 1b clinical trial results for brezosiran (ALN-HTT02), demonstrating deep and durable reductions of mutant huntingtin protein in patients with Huntington's disease.
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.